{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:11:59Z","timestamp":1790327519053,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational Med"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective second\u2010line therapy is urgently needed for patients with driver\u2010gene\u2010negative non\u2010squamous non\u2010small cell lung cancer (nsqNSCLC) who progress after first\u2010line immunochemotherapy. This study aims to evaluate the efficacy and safety of bevacizumab combined with nab\u2010paclitaxel and platinum (the BAP regimen) in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, single\u2010arm, single\u2010centre study enrolled 56 patients with advanced driver\u2010gene\u2010negative nsqNSCLC failing first\u2010line immunochemotherapy. Patients received bevacizumab, nab\u2010paclitaxel, and platinum (carboplatin or cisplatin) for 4\u20136 cycles, followed by bevacizumab maintenance. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression\u2010free survival (PFS), overall survival (OS), disease control rate (DCR) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All patients had failed first\u2010line platinum\u2010based immunochemotherapy. The confirmed ORR was 46.4% (26\/56, 95% confidence interval [CI]: 34.0%\u201359.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), and DCR was 75%. The median PFS and OS were 5.6 (95% CI: 4.35\u20136.79) and 18.8 (95% CI: 10.31\u201327.24) months. Patients with \u2264 2 metastatic organs had a significantly longer median PFS than those with\u00a0&gt;2 metastatic organs (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.014). Multivariable Cox analysis showed that a platinum\u2010free interval\u00a0&lt;6 months was an independent biomarker of worse PFS. The safety profile was manageable. Plasma proteomics identified baseline high TWEAK level as a potential biomarker for response to both the second\u2010line BAP regimen and first\u2010line immunochemotherapy. Patients with high baseline TWEAK levels before first\u2010line immunochemotherapy showed a median OS of 39.8 months under this sequential treatment modality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The BAP regimen demonstrated preliminary efficacy with manageable safety as a second\u2010line therapy for patients with advanced driver\u2010gene\u2010negative nsqNSCLC after immunochemotherapy. Plasma TWEAK levels may serve as a potential biomarker to help identify patients who might benefit most from this sequential treatment modality, pending further independent validation. Further studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ctm2.70814","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:37:06Z","timestamp":1789115826000},"source":"Crossref","is-referenced-by-count":0,"title":["Bevacizumab plus nab\u2010paclitaxel and platinum as second\u2010line therapy for driver\u2010gene\u2010negative non\u2010squamous non\u2010small cell lung cancer after immunochemotherapy: A prospective single\u2010arm single\u2010centre study"],"prefix":"10.1002","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4321-0695","authenticated-orcid":false,"given":"Ying","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunbo","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-3832","authenticated-orcid":false,"given":"Zhihuang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1791-5763","authenticated-orcid":false,"given":"Chenchen","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Oncology The Second Affiliated Hospital of Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8051-9595","authenticated-orcid":false,"given":"Zezhou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"},{"name":"Department of Cancer Prevention Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Shanghai Municipal Hospital Oncological Specialist Alliance  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-4249","authenticated-orcid":false,"given":"Bo","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6874-2405","authenticated-orcid":false,"given":"Xinmin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-1598","authenticated-orcid":false,"given":"Xianghua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-2219","authenticated-orcid":false,"given":"Jialei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Centre  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"},{"name":"Institute of Thoracic Oncology Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010023\u201001740\u2010y"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(19)30084\u20100"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5258"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010025\u201001061\u20107"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201002808\u2010y"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00912"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.004"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02166"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.05.020"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00733"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201001544"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221099399"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.12.009"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.02.002"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010022\u201009441\u20103"},{"key":"e_1_2_14_18_1","article-title":"Phase II study of platinum re\u2010administration in non\u2010small cell lung cancer following chemoimmunotherapy resistance","volume":"17","author":"Ninomiya K","year":"2025","journal-title":"Cureus"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759\u20107714.15107"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)60845\u2010X"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30673\u20109"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.027"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)32517\u2010X"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229\u20103485.83221"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-1018"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.05.021"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9039"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010025\u201058186\u20107"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8429"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010024\u201002092\u2010x"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.853324"}],"container-title":["Clinical and Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ctm2.70814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ctm2.70814","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ctm2.70814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:49:35Z","timestamp":1790326175000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ctm2.70814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ctm2.70814"],"URL":"https:\/\/doi.org\/10.1002\/ctm2.70814","archive":["Portico"],"relation":{},"ISSN":["2001-1326","2001-1326"],"issn-type":[{"value":"2001-1326","type":"print"},{"value":"2001-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"e70814"}}